XERS Q3 2019 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$323,000-44.5% YoY

Gross Profit

$313,00096.9% margin

Operating Income

-$30M-9313.3% margin

Net Income

-$33M-10165.9% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$128M

Total Liabilities

$84M

Stockholders' Equity

$44M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$323,000	$582,000	-44.5%
Gross Profit	$313,000	$582,000	-46.2%
Operating Income	-$30M	-$15M	-101.3%
Net Income	-$33M	-$15M	-122.4%